Antibodies and Fc-fusion antibody-like proteins have become successful biologics
developed for cancer treatment, passive immunity against infection, addiction, and …

Since the first description in 1989 of CD4‐Fc‐fusion antagonists that inhibit human immune
deficiency virus entry into T cells, Fc‐fusion proteins have been intensely investigated for …

Many of the currently available COVID-19 vaccines and therapeutics are not effective
against newly emerged SARS-CoV-2 variants. Here, we developed the metallo-enzyme …

In recent years, there has been a surge in the research and development of novel molecules
as potential therapeutic alternatives to traditional treatments (such as intravenous …

The novel coronavirus is not only causing respiratory problems, but it may also damage the
heart, kidneys, liver, and other organs; in Wuhan, 14 to 30% of COVID‐19 patients have lost …

Synthetic fusion proteins can be designed to achieve improved properties or new
functionality by synergistically incorporating multiple proteins into one complex. The fusion …

Stable, effective, easy-to-manufacture vaccines are critical to stopping the COVID-19
pandemic resulting from the coronavirus SARS-CoV-2. We constructed a vaccine candidate …

The platform technology of fragment crystallizable (Fc) fusion, in which the Fc region of an
antibody is genetically linked to an active protein drug, is among the most successful of a …

Since the first description of the administration of high doses of pooled serum IgG, also
referred to as intravenous IgG (IVIg) therapy, as being able to ameliorate various …

The relevance of protein-glycan interactions in immunity has long been underestimated. Yet,
the immune system possesses numerous classes of glycan-binding proteins, so-called …